Surrozen (NASDAQ:SRZN) Director Tim Kutzkey Acquires 5,266 Shares

Surrozen, Inc. (NASDAQ:SRZN) Director Tim Kutzkey purchased 5,266 shares of the business’s stock in a transaction on Thursday, December 4th. The shares were acquired at an average price of $17.35 per share, with a total value of $91,365.10. Following the purchase, the director owned 965,509 shares of the company’s stock, valued at approximately $16,751,581.15. This trade represents a 0.55% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Tim Kutzkey also recently made the following trade(s):

• On Friday, December 5th, Tim Kutzkey acquired 30,884 shares of Surrozen stock. The shares were bought at an average cost of $19.54 per share, for a total transaction of $603,473.36.
• On Thursday, November 13th, Tim Kutzkey acquired 315,457 shares of Surrozen stock. The stock was bought at an average price of $12.65 per share, for a total transaction of $3,990,531.05.

Surrozen Price Performance

Shares of Surrozen stock traded up $0.01 during midday trading on Monday, hitting $20.47. 110,179 shares of the company were exchanged, compared to its average volume of 30,511. The firm has a market cap of $175.45 million, a P/E ratio of -0.92 and a beta of 0.62. Surrozen, Inc. has a 52 week low of $5.90 and a 52 week high of $21.33. The firm has a 50 day simple moving average of $13.90 and a 200-day simple moving average of $11.32.

Surrozen (NASDAQ:SRZN) last announced its quarterly earnings results on Friday, November 7th. The company reported ($3.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). The company had revenue of $0.98 million during the quarter. Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. Equities research analysts expect that Surrozen, Inc. will post -8.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a research report on Wednesday, October 8th. Wall Street Zen raised Surrozen to a “sell” rating in a report on Friday, November 28th. Finally, Lifesci Capital upgraded Surrozen to a “strong-buy” rating in a research report on Thursday, November 13th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Surrozen has a consensus rating of “Moderate Buy” and an average target price of $38.50.

Institutional Investors Weigh In On Surrozen

Several institutional investors have recently modified their holdings of the business. Citadel Advisors LLC boosted its holdings in shares of Surrozen by 32.8% in the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock valued at $179,000 after buying an additional 3,424 shares during the period. Geode Capital Management LLC lifted its position in Surrozen by 22.6% in the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after acquiring an additional 5,702 shares in the last quarter. Heights Capital Management Inc. acquired a new position in Surrozen in the 1st quarter worth $524,000. Armistice Capital LLC bought a new position in Surrozen during the 2nd quarter worth about $536,000. Finally, Woodline Partners LP acquired a new stake in shares of Surrozen in the 3rd quarter valued at about $621,000. Institutional investors and hedge funds own 66.57% of the company’s stock.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.